Concepedia

Lisa Blaydorn

LB

Statistics

Publications

6

Citations

504

H-Index

6

Active since

2011

Affiliations

Western Regional Medical Center(Current)

Goodyear (United States)

South Texas Accelerated Research Therapeutics

Translational Genomics Research Institute

Lisa Blaydorn is an author at Western Regional Medical Center specializing in medicine, pharmacology, and oncology.

Publications per year

2011–2021

6

Publications

6

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

Glen J. Weiss, Lisa Blaydorn, Julia Beck et al. · Investigational New Drugs · 2017 · 215 citations

Medicine, Oncology, Pharmacology +13

A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)

Glen J. Weiss, Jordan Waypa, Lisa Blaydorn et al. · British Journal of Cancer · 2017 · 132 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

Amita Patnaik, Glen J. Weiss, John E. Leonard et al. · Clinical Cancer Research · 2015 · 64 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

Glen J. Weiss, Manuel Hidalgo, Mitesh J. Borad et al. · Investigational New Drugs · 2011 · 41 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

18‐<scp>FDG PET</scp>/<scp>CT</scp> assessment of basal cell carcinoma with vismodegib

Curtis Thacker, Glen J. Weiss, Raoul Tibes et al. · Cancer Medicine · 2012 · 28 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

1–5 of 6